- Clinical Essentials from HIV Med
- 1 comment
Data from a Dutch nationwide prospective study.
Study identifies risk factors for local infection after major oncologic surgery.
Phase 3 data suggest a need for more specific P13K inhibitors.
Most favorable OS seen in patients with head and neck lesions.
Modified guidelines for SBRT in NSCLC | Osimertinib vs EGFR-TKIs in NSCLC | FDA approves solid tumor genetic test | FDG-PET unreliable in lung cancer diagnosis.
The prevalence of PE and DVT was 1.1% and 1.4%, respectively.
Metformin and stroke risk | CAC predicts CVD risk in diabetes | What is optimal diabetes screening frequency?
Anti-TNFα agents, on the other hand, are linked to reduced risk.
Results of a small study.
Modeling of patient-level data suggests cost, QoL benefits.
Treatment may benefit statin-intolerant patients.
Real-world study suggests older age may be tied to better clinical outcome.
Data from the SPARX phase 2 randomized controlled trial.
Latest review gives mixed answers.
Data from a small randomized controlled trial.